Work

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Year: 2019

Type: article

Study design: Clinical Trial

Source: The Lancet HIV

DOI: 10.1016/s2352-3018(19)30080-3

Authors: Hans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, Helmut Albrecht, Paul E Sax, Franco Maggiolo, Catherine Creticos, Claudia T Martorell, Xuelian Wei, Rima Acosta, Sean E Collins, Diana Brainard, Hal Martin

Institutions: Universität Hamburg, Hospital Universitario La Paz, Mercer University, University of South Carolina, Harvard University, Ospedale Papa Giovanni XXIII, Howard Brown Health Center, Infectious Diseases and the Research Institute, Gilead Sciences (United States)

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Gilead Sciences

OpenAlex ID: W4244459571

FWCI: 13.8

Cites: 13

Cited by: 140

Related to: 10